Reports
Sale
Global Plasma Fractionation Market Share, Trends, Analysis, Forecast: By Product: Immunoglobulins, Coagulation Factor Concentrates, Albumin, Protease Inhibitor, Others; By Method: Centrifugation, Depth Filtration, Chromatography, Others; By Application: Neurology, Others; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Global Plasma Fractionation Market Outlook
The global plasma fractionation market value was USD 27.96 billion in 2023, driven by the growing demand for plasma-derived therapies across the globe. The market size is anticipated to grow at a CAGR of 6.7% during the forecast period of 2024-2032 to achieve a value of USD 50.11 billion by 2032.
Key Trends in the Market
Plasma fractionation is the process of breaking down and separating the different components of blood plasma collected from donors. The proteins separated from the plasma are used as a therapeutic product for prevention and treatment of life-threatening diseases such as immunological disorders, blood clotting disorders, and others.
- Respiratory diseases along with AATD (Alpha-1-antitrypsin deficiency) are increasing and becoming widely prevalent. More people are undergoing therapy for treatment of such disease which is contributing to the growth of the market globally. AATD is an unrecognised chronic metabolic genetic disorder which can also cause emphysema.
- Bleeding disorders such as haemophilia have been rising which are characterised by impaired blood coagulation. One of the main applications of plasma fractionation is the treatment of haemophilia which is helping in the growth of the plasma fractionation market.
- Plasma collection centres are spread all over the world in large numbers so that human plasma that can be used for treatment of more individuals without facing shortages. Post-collection, there is need for plasma fractionation, making it a key trend for the market.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
Based on product, the plasma fractionation market can be segmented into immunoglobulins, coagulation factor concentrates, albumin, protease inhibitors, and others. On the basis of application, it can be divided into neurology, immunology, haematology, rheumatology, and others. Based on processing technology it is divided into ion exchange chromatography, affinity chromatography, cryopreservation, ultrafiltration, and microfiltration. By end use the market is divided into hospitals and clinics, clinical research laboratories, academic institutes, and others. On a regional basis, the market can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East, and Africa.
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global plasma fractionation market, covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.
- CSL Plasma LLC
- Grifols, S.A.
- Takeda Pharmaceutical Company Limited
- Biotest Group
- Baxter International Inc.
- Others
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Share by Product Type
Immunoglobulins hold a significant share in the market for plasma fractionation because of their ability to treat autoimmune diseases and increase immune response. Coagulation factor concentrates help in the formation of blood clots whereas albumin is involved in the movement of molecules through blood. HIV progression is slowed down with the help of protease inhibitors. All these products largely contribute to the growth of the market.\
Market Share by End Use
Improved infrastructure and facilities in hospitals have made it the largest shareholder in the market for plasma fractionation. Hospitals and clinics are now providing treatment facilities for various autoimmune diseases using plasma products which is why it is predicted to dominate the market in the forecast period as well. Clinical research laboratories are also researching for new and innovative therapy techniques, contributing to the growth of the plasma fractionation market.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Competitive Landscape
CSL Plasma LLC was founded in 1916 and has its headquarter in Florida, United States. Its parent company CSL Behring makes use of human plasma to treat bleeding disorders, neurological disorders, immune deficiency, inherited respiratory disease, and hereditary angioedema.
Grifols S.A. was founded in 1940. Based out of Barcelona, Spain, it is a Spanish company specialising in the manufacture of pharmaceuticals and chemicals. It mainly produces blood plasma-based products among other instruments, and reagents to be used in clinical testing.
Biotest Group is known globally for developing and supplying biotherapeutic drugs and plasma protein products. It was established in 1946 and has its headquarter in Dreieich, Germany.
Other market players include Takeda Pharmaceutical Company Limited, and Baxter International Inc., among others.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment
|
| Breakup by Product |
|
| Breakup by Method |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Plasma Fractionation Market Overview
3.1 Global Plasma Fractionation Market Historical Value (2017-2023)
3.2 Global Plasma Fractionation Market Forecast Value (2024-2032)
4 Global Plasma Fractionation Market Landscape
4.1 Global Plasma Fractionation Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Plasma Fractionation Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Method
4.2.3 Analysis by Applications
5 Global Plasma Fractionation Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Plasma Fractionation Market Segmentation
6.1 Global Plasma Fractionation Market by Product
6.1.1 Market Overview
6.1.2 Immunoglobulins
6.1.3 Coagulation Factor Concentrates
6.1.4 Albumin
6.1.5 Protease Inhibitor
6.1.6 Others
6.2 Global Plasma Fractionation Market by Method
6.2.1 Market Overview
6.2.2 Centrifugation
6.2.3 Depth Filtration
6.2.4 Chromatography
6.2.5 Others
6.3 Global Plasma Fractionation Market by Application
6.3.1 Market Overview
6.3.2 Neurology
6.3.3 Hematology
6.3.4 Oncology
6.3.5 Immunology
6.3.6 Pulmonology
6.3.7 Others
6.4 Global Plasma Fractionation Market by End User
6.4.1 Market Overview
6.4.2 Hospitals and Clinics
6.4.3 Clinical Research Laboratories
6.4.4 Academic Institutes
6.4.5 Others
6.5 Global Plasma Fractionation Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Plasma Fractionation Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Plasma Fractionation Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Plasma Fractionation Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Plasma Fractionation Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Plasma Fractionation Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 CSL Plasma LLC
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Grifols, S.A.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Takeda Pharmaceutical Company Limited
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Biotest Group
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Baxter International Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 OCTAPHARMA AG
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 KEDRION S.P.A
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 LFB S.A.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 BIOTEST AG
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 SANQUIN
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 BIO PRODUCTS LABORATORY LTD.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 INTAS PHARMACEUTICALS LTD.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 GC Pharma
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Emergent Biosolutions
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Japan Blood Products Organisation
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
18 Global Plasma Fractionation Market- Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The plasma fractionation market was valued at USD 27.96 billion in 2023.
The market is expected to grow at a CAGR of 6.7% from 2024 to 2032 to reach USD a value of USD 50.11 billion by 2032.
The major market drivers are increasing geriatric population and increasing use of immunoglobulins.
Major trends in the market are prevalence of respiratory diseases and bleeding disorders and increase in the number of plasma collection centres worldwide.
The regional markets can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa.
Key players in the global plasma fractionation market are CSL Plasma LLC, Grifols, S.A., Takeda Pharmaceutical Company Limited, Biotest Group, and Baxter International Inc., among others.
Plasma fractionation is the process of breaking down and separating the different components of blood plasma collected from donors.
The market is segmented based on product, application, processing technology, end use, and region.
Proteins separated from plasma are used as a therapeutic product for prevention and treatment of life-threatening diseases such as immunological disorders, blood clotting disorders, and others.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER